Radiopharmaceuticals in Nuclear Medicine Market - Global Outlook and Forecast 2022-2028 Bharat Book Bureau Provides the Trending Industry Research Report on“Radiopharmaceuticals in Nuclear Medicine Market - Global Outlook and Forecast 2022-2028”under Life Sciences Market Research Report. The report offers a collection of superior Market research, Market analysis, competitive intelligence and Market reports. Executive Summary This report contains market size and forecasts of Radiopharmaceuticals in Nuclear Medicine in global, including the following market information:
Global Radiopharmaceuticals in Nuclear Medicine Market Revenue, 2017-2022, 2023-2028, ($ millions) Global Radiopharmaceuticals in Nuclear Medicine Market Sales, 2017-2022, 2023-2028, (K MT) Global top five Radiopharmaceuticals in Nuclear Medicine companies in 2021 (%) The global Radiopharmaceuticals in Nuclear Medicine market was valued at 4943.7 million in 2021 and is projected to reach US$ 6857.2 million by 2028, at a CAGR of 4.8% during the forecast period. The U.S. Market is Estimated at $ Million in 2021, While China is Forecast to Reach $ Million by 2028. Diagnostic Radiopharmaceuticals Segment to Reach $ Million by 2028, with a % CAGR in next six years. The global key manufacturers of Radiopharmaceuticals in Nuclear Medicine include Bracco Imaging S.P.A., Cambridge Isotope Laboratories, Inc., Cardinal Health, Inc., Covidien, Plc, Eczacibasi-Monrol, Fujifilm Holdings Corporation, GE Healthcare (Subsidiary Of General Electric Company), IBA Group and Isotec, Inc. (Sigma-Aldrich), etc. In 2021, the global top five players have a share approximately % in terms of revenue. MARKET MONITOR GLOBAL, INC (MMG) has surveyed the Radiopharmaceuticals in Nuclear Medicine manufacturers, suppliers, distributors and industry experts on this industry, involving the sales, revenue, demand, price change, product type, recent development and plan, industry trends, drivers, challenges, obstacles, and potential risks.